Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Bill is filed in its originating chamber and assigned a number.
Filed in the House.
Next: In Committee
Members of the committee(s) the bill was referred to
Requires Medicare drug plans to include generic drugs and biosimilar products on their formularies.
The problem
Medicare drug plans may exclude affordable generic and biosimilar options from their formularies, limiting patient access to lower-cost medications.
The proposal
Amends Medicare Part D rules to mandate that prescription drug plan sponsors include certain generic drugs and biosimilar biological products on their formularies.
The impact
Medicare beneficiaries gain greater access to affordable medications; insurers face formulary restrictions; pharmaceutical companies experience demand shifts toward generics and biosimilars.
Generic drugs and biosimilars are typically much cheaper than brand-name medications. Seniors on fixed incomes would have better access to affordable treatments, reducing out-of-pocket expenses.
Requiring inclusion of generic and biosimilar options ensures patients have these choices available. This expands treatment options for Medicare beneficiaries with various health conditions.
Wider use of generics and biosimilars lowers overall medication costs. This could reduce total Medicare spending and lower premiums for beneficiaries.
Lower costs remove financial barriers to taking necessary medications. Better medication adherence improves health outcomes for chronic disease management.
Drug plans lose the ability to selectively exclude drugs from formularies for cost management. This limits insurers' negotiating power and cost-control strategies.
Mandating drug inclusion could increase insurance companies' costs, which may be passed to beneficiaries through higher premiums or plan costs.
Some argue formulary restrictions exist to ensure medication quality and appropriateness. Mandatory inclusion could compromise clinical decision-making by plans.
The bill specifies 'certain' generics and biosimilars but lacks clear detail on which drugs qualify. This vagueness could create implementation challenges and disputes.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.